The study, published in Supportive Care in Cancer, was led by Syed E. Pasha of the University of Houston and HCA Houston Healthcare Kingwood, together with colleagues from MountainView Hospital and Texas Oncology centers. The team set out to answer a deceptively simple question: do patients with diffuse large B-cell lymphoma, an aggressive and rapidly treated lymphoma, experience different kidney outcomes than patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, an indolent disease that often smolders for years before requiring therapy? Comparative renal data between these two populations had been scarce, despite the fact that both cancers are common and both are treated with regimens known to stress the kidneys.

To answer the question, the researchers turned to the TriNetX Global Collaborative Network, a federated database drawing de-identified electronic health records from 143 healthcare organizations. Data were extracted on May 9, 2025. Adults with a coded diagnosis of diffuse large B-cell lymphoma or of chronic lymphocytic leukemia and small lymphocytic lymphoma were identified using standard ICD-10 diagnostic codes. To make the two groups as comparable as possible, the investigators used a statistical technique called propensity score matching, pairing each patient with a counterpart from the other cohort who shared the same age, sex, race, and ethnicity. This one-to-one matching produced two demographically indistinguishable groups, with standardized mean differences between them ranging from just 0.001 to 0.038, values so small they indicate near-perfect balance.

The final analysis included 19,438 patients, evenly split with 9,719 in each cohort. Kidney outcomes were tracked from the first day after the index diagnosis through each patient’s available follow-up, an open-ended window rather than a fixed observation period. The researchers looked for two distinct conditions: acute kidney injury, the sudden loss of renal function that can develop within hours or days, and chronic kidney disease, the gradual, often irreversible decline in filtration capacity that unfolds over months and years. Statistical comparisons relied on two-proportion z-tests, generating risk differences, risk ratios, and odds ratios with 95 percent confidence intervals.

The results revealed a fascinating split. Acute kidney injury struck 22.9 percent of the diffuse large B-cell lymphoma patients compared with 20.9 percent of the chronic lymphocytic leukemia and small lymphocytic lymphoma group. That two-percentage-point gap was statistically significant, with a risk ratio of 1.094 and an odds ratio of 1.122, and a p-value of 0.001. In other words, the aggressive lymphoma carried a modestly higher risk of sudden renal failure. The pattern flipped for chronic kidney disease. Here, 18.8 percent of the lymphoma patients developed the condition versus 22.7 percent of the leukemia and indolent lymphoma group, a negative risk difference of 4.0 percent, with a risk ratio of 0.825 and an odds ratio of 0.785, and a p-value below 0.001. The slower cancer, paradoxically, left a heavier mark on long-term kidney health.

The biology behind this divergence makes intuitive sense when one considers how each disease and its treatment unfold. Diffuse large B-cell lymphoma grows quickly and is typically treated with intensive chemoimmunotherapy, most commonly regimens built around rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. Rapid tumor cell death can trigger tumor lysis syndrome, a cascade in which potassium, phosphate, and uric acid flood the bloodstream and crystallize in renal tubules, a well-documented cause of acute kidney injury. High-dose chemotherapy agents themselves, along with the infections, dehydration, and intensive care admissions that can accompany aggressive treatment, all add to the short-term renal assault.

Chronic lymphocytic leukemia, by contrast, is a disease of accumulation and time. Patients frequently live with it for a decade or more, and even those who never require treatment face aging kidneys, cumulative exposure to nephrotoxic drugs across successive lines of therapy, and immune complications. Modern targeted therapies such as ibrutinib, which has transformed outcomes in this disease, carry their own renal baggage; real-world analyses of hundreds of treated patients have documented a spectrum of toxicities that can include hypertension and kidney dysfunction. Over years of surveillance, treatment, and comorbidity, the indolent disease’s patient population gradually accrues the chronic damage that shows up as chronic kidney disease. The new data, showing a 22.7 percent chronic kidney disease rate in this group, align with that clinical picture.

The authors are careful to frame their findings as hypothesis-generating rather than definitive. The matching algorithm balanced demographics but did not capture comorbidities such as diabetes, hypertension, or pre-existing renal impairment, all of which are powerful drivers of kidney disease and may differ systematically between the two cancer populations. Follow-up duration was also not matched, and the open-ended observation window means patients in one group may simply have been watched longer. Absolute differences between the cohorts were small, in the range of two to four percentage points, and the study relied on administrative diagnostic codes rather than laboratory-verified kidney function measures. The research was supported in whole or in part by HCA Healthcare, though the authors declare no competing interests, and the views expressed are those of the authors alone.

Even with those caveats, the study carries practical weight for the growing field of onco-nephrology, the discipline that sits at the intersection of cancer care and kidney medicine. Acute kidney injury in patients with hematological malignancies is known to worsen remission rates and survival, and chronic kidney disease constrains which cancer therapies a patient can safely receive, since many agents require dose adjustment or are contraindicated in renal impairment. If the pattern observed here holds up, supportive care pathways might reasonably emphasize vigilant short-term renal monitoring, hydration protocols, and uric acid management around the intensive treatment phases of aggressive lymphoma, while building durable long-term nephrology follow-up into the care of chronic lymphocytic leukemia survivors, whose kidneys face a marathon rather than a sprint.

What comes next is confirmation. The authors themselves call for comorbidity-adjusted analyses and prospective studies to verify whether the renal risk differences survive when diabetes, hypertension, baseline kidney function, and treatment exposure are properly accounted for. Until then, the message for clinicians is one of heightened awareness rather than alarm: both cancer subtypes deserve deliberate attention to the kidneys, but the timing and nature of that attention may need to differ. A single dataset of nearly twenty thousand matched patients cannot settle every question, but it has usefully drawn a map, pointing oncologists toward the moments in each disease trajectory where the kidneys are most vulnerable, and reminding the wider medical community that surviving cancer is only half the story, with protecting the organs that carry patients through survivorship being the other half.

Subject of Research: Comparative renal outcomes of acute kidney injury and chronic kidney disease in diffuse large B-cell lymphoma versus chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care

Article References: Pasha, S. E., Khalique, S., Haddadin, R., Mazharuddin, S., & Khoury, P. N. (2026). Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care. Supportive Care in Cancer, 34(10), Article 1029. https://doi.org/10.1007/s00520-026-11256-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11256-y

Keywords: diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, acute kidney injury, chronic kidney disease, supportive oncology, onco-nephrology, nephrotoxicity, TriNetX, propensity score matching, real-world data, tumor lysis syndrome

Zanubrutinib belongs to a class of targeted drugs known as Bruton’s tyrosine kinase inhibitors, or BTK inhibitors, which block a signaling protein that B cells, the immune cells that turn malignant in chronic lymphocytic leukemia, rely on for survival and proliferation. First-generation inhibitors such as ibrutinib transformed outcomes for this patient population but carried a burden of off-target effects, because they also inhibited related kinases including those involved in cardiac rhythm, platelet aggregation, and other signaling pathways. Zanubrutinib was engineered for greater selectivity, binding BTK more completely while sparing neighboring targets, and the new cohort study set out to test whether that improved pharmacological profile translates into better tolerability and sustained disease control outside the carefully curated environment of a clinical trial.

The researchers interrogated treatment patterns across the full cohort with unusual granularity. Therapy was discontinued in 76 patients, or 18.5 percent of the total, but the reasons tell an encouraging story. Disease progression accounted for only 32 discontinuations, or 7.8 percent of all patients, meaning the vast majority of patients who stopped the drug did so for reasons unrelated to treatment failure. Patient preference led 25 patients, or 6.1 percent, to discontinue, adverse events prompted 15 patients, or 3.7 percent, to stop, and four patients, or 1.0 percent, died of unknown causes. In an era when treatment duration on continuous oral therapy is a key measure of a drug’s real-world value, these numbers suggest that zanubrutinib keeps patients on treatment and keeps their disease in check for extended periods.

Perhaps the most clinically consequential finding concerns dose reductions, a topic that has generated anxiety among both oncologists and patients. Forty-six patients, or 11.2 percent of the cohort, required at least one dose reduction, most commonly because of adverse events, which affected 17 patients, or 4.1 percent, or because of patient preference, cited by 26 patients, or 6.3 percent. The critical question has always been whether lowering the dose compromises efficacy. The answer from this cohort appears to be no. Among the 46 patients who reduced their dose, the researchers observed no cases of disease progression or death after the reduction occurred, over a median follow-up of 10.9 months from the first dose modification. While the follow-up window is relatively short and the subgroup modest in size, the signal is reassuring for the many patients who need to taper their dose to manage side effects.

The study also shed light on a growing phenomenon in leukemia care: switching between BTK inhibitors. Fifty-four patients in the cohort moved to zanubrutinib from another BTK inhibitor without any evidence of disease progression, meaning they switched for tolerability or convenience rather than treatment failure. Thirty-two of these patients made the move because of adverse events on their previous drug, 19 because of patient preference, and four for unknown reasons, with some reasons overlapping. The median duration of zanubrutinib treatment after the switch was 10.1 months among patients who switched due to side effects and 16.5 months among those who switched by preference. Most notably, progression-free survival had not been reached in either group at the time of analysis, indicating that patients who transition from an older BTK inhibitor to zanubrutinib for non-progressive reasons can continue to achieve durable disease control on the newer agent.

From a technical standpoint, the study’s design merits attention. The investigators conducted a retrospective, multicenter cohort analysis drawing on data from hospitals across China, including Peking University People’s Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanfang Hospital, West China Hospital, and several others, with Peking University People’s Hospital serving as the central ethics committee. The primary endpoint was progression-free survival, the standard measure of how long patients live without their disease worsening, analyzed with confidence intervals to quantify uncertainty. The three-year PFS estimate of 91.6 percent for treatment-naive patients carried a 95 percent confidence interval of 83.8 to 95.8 percent, while the 83.2 percent estimate for later-line patients spanned 74.6 to 89.1 percent. These intervals, while wide in places due to the evolving follow-up time, place real-world outcomes squarely in the territory previously reported in registration trials, a consistency that strengthens confidence in the drug’s effectiveness.

The distinction between initial and later-line therapy matters enormously in chronic lymphocytic leukemia, an indolent malignancy that predominantly affects older adults and often follows a relapsing course over many years. Patients receiving zanubrutinib as initial therapy had not been exposed to prior BTK inhibition and typically had fewer accumulated resistance mechanisms. Those receiving it later had often been through chemoimmunotherapy or earlier targeted agents. The roughly eight-percentage-point gap in three-year progression-free survival between the two groups is consistent with the expected biology, yet the fact that later-line patients still achieved better than 83 percent freedom from progression at three years underscores how much the BTK inhibitor class has reshaped the prognosis of relapsed and refractory disease, which was historically one of the most difficult scenarios to manage.

Why does real-world evidence of this kind matter so much? Registration trials enroll selected patients, often excluding those with significant comorbidities, competing medications, or atypical disease features, and they monitor adherence intensively. Routine practice is different. Patients forget doses, stop drugs because they feel well, reduce doses on their own initiative, and switch therapies based on quality-of-life considerations that never appear in a case report form. By documenting that only 3.7 percent of patients discontinued zanubrutinib because of adverse events, and that dose reductions did not precipitate disease progression, this nationwide cohort provides the kind of pragmatic evidence that health systems, guideline committees, and prescribing physicians need when weighing treatment options for a disease that may require years of continuous oral therapy.

The findings also carry implications for how clinicians counsel patients about side effect management. Patient preference was the single most common reason for both dose reduction and discontinuation in this cohort, a reminder that shared decision-making is not a formality but a genuine determinant of treatment trajectories. Some patients in the study chose to reduce or stop their medication despite adequate tolerability, and the data suggest that, at least within the observed follow-up, such choices did not immediately translate into disease progression. That said, the authors and the broader hematology community would caution that longer observation is needed before dose attenuation can be considered fully equivalent to continuous full-dose therapy, particularly given the indolent nature of the disease and the possibility of late relapse.

Taken together, the study offers a comprehensive portrait of zanubrutinib as it is actually used: a drug with high selectivity for its target, low rates of discontinuation for toxicity, reassuring outcomes after dose modification, and strong progression-free survival in both first-line and later-line settings. As BTK inhibitors continue to evolve and as fixed-duration combinations challenge the paradigm of continuous therapy, cohorts like this one, registered as NCT06489184 on ClinicalTrials.gov, will remain essential for understanding how these powerful targeted agents perform in the hands of real patients and real physicians, far from the protocolized confines of the clinical trial.

Subject of Research: Real-world effectiveness, dose modification and discontinuation patterns of the BTK inhibitor zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort

Article References: Yang, S., Zhu, H., Hu, L., Feng, R., Guo, X., Niu, T., Shen, K., Li, Z., Dong, Y., Wang, B., Su, L., Wang, L., Wang, L., Sun, W., Fang, F., Zhao, Y., Huang, X., & Li, J. (2026). Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17043-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17043-6

Keywords: zanubrutinib, chronic lymphocytic leukemia, small lymphocytic lymphoma, BTK inhibitor, progression-free survival, dose reduction, real-world evidence, drug discontinuation, adverse events, hematology, targeted therapy, BMC Cancer